shutterstock_1653845269_taljat_david
Taljat David / Shutterstock.com
20 September 2022Big PharmaStaff Writer

Swiss watchdog investigates Novartis over patent use

Authority carries out dawn raid at Novartis’ premises | Probe focuses on the alleged unlawful use of a skincare patent to bar competition

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
22 July 2022   The pair are rapped for overcharging the NHS | Unfair prices for an epilepsy drug lasted four years | Costs leapt from £2m to £50m in one year after the companies' “illegal exploitation” of market position.
Big Pharma
23 June 2022   The US Court of Appeals for the Federal Circuit has held that a patent covering Novartis’ multiple sclerosis drug Gilenya is invalid, potentially opening the floodgates for the introduction of generic versions of the drug.
Americas
22 September 2022   Federal Circuit denies petition to rehear dispute over multiple sclerosis medicine | Company will petition highest court over invalidity ruling.

More on this story

Big Pharma
22 July 2022   The pair are rapped for overcharging the NHS | Unfair prices for an epilepsy drug lasted four years | Costs leapt from £2m to £50m in one year after the companies' “illegal exploitation” of market position.
Big Pharma
23 June 2022   The US Court of Appeals for the Federal Circuit has held that a patent covering Novartis’ multiple sclerosis drug Gilenya is invalid, potentially opening the floodgates for the introduction of generic versions of the drug.
Americas
22 September 2022   Federal Circuit denies petition to rehear dispute over multiple sclerosis medicine | Company will petition highest court over invalidity ruling.

More on this story

Big Pharma
22 July 2022   The pair are rapped for overcharging the NHS | Unfair prices for an epilepsy drug lasted four years | Costs leapt from £2m to £50m in one year after the companies' “illegal exploitation” of market position.
Big Pharma
23 June 2022   The US Court of Appeals for the Federal Circuit has held that a patent covering Novartis’ multiple sclerosis drug Gilenya is invalid, potentially opening the floodgates for the introduction of generic versions of the drug.
Americas
22 September 2022   Federal Circuit denies petition to rehear dispute over multiple sclerosis medicine | Company will petition highest court over invalidity ruling.